Ipsen announces U.S. FDA submission acceptance of its supple

Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma

Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Shanghai , China , Cambridge , Cambridgeshire , United Kingdom , France , Paris , France General , Taipei , T Ai Pei , Taiwan , San Francisco , California , United States , Saclay , American , Howard Mayer , Ipsen Euronext , Elizabeth Kalina , Ipsen Pharma , Craig Marksvice , Drug Administration , Communications Patient Advocacy , Joanna Parishglobal Head Of Franchise Communications , Head Of Research , Supplemental New Drug Application , Executive Vice President , Prescription Drug User Fee Act , Ipsen Fast Track , Reproductive Potential , Prescribing Information , Rare Disease , Sponsored Leveli American Depositary Receipt , French Autorit , Des March , Universal Registration Document , Marksvice President , Parishglobal Head , Franchise Communications , Vice President , Open Label Phase , Liposomal Irinotecan , Metastatic Pancreatic Ductal Adenocarcinoma , Cancers Symposium ,